• 1. Base catalysed rearrangements involving ylide intermediates. Part 18. Competing [1,2], [1,3], and [1,4] rearrangements of ammonium ylides
  Kan Chantrapromma,W. David Ollis,Ian O. Sutherland J. Chem. Soc. Perkin Trans. 1 1983 1049
• 2. Chiral chlorobismuthines stabilized by the intramolecular coordination of an N,N-dimethylamino group: X-ray structure analysis, asymmetric induction at the bismuth centre, and dynamic behaviour in solution
  Hitomi Suzuki,Toshihiro Murafuji,Yoshihiro Matano,Nagao Azuma J. Chem. Soc. Perkin Trans. 1 1993 2969
• 3. Highly enantioselective elimination of meso-compounds
  Hiroshi Kashihara,Hiroshi Suemune,Tetsuya Kawahara,Kiyoshi Sakai J. Chem. Soc. Perkin Trans. 1 1990 1663
• 4. Mechanistic study of the selective hydrogenation of carboxylic acid derivatives over supported rhenium catalysts
  Takashi Toyao,Kah Wei Ting,S. M. A. Hakim Siddiki,Abeda S. Touchy,Wataru Onodera,Zen Maeno,Hiroko Ariga-Miwa,Yasuharu Kanda,Kiyotaka Asakura,Ken-ichi Shimizu Catal. Sci. Technol. 2019 9 5413
• 5. Design and evaluation of switchable-hydrophilicity solvents
  Jesse R. Vanderveen,Jeremy Durelle,Philip G. Jessop Green Chem. 2014 16 1187

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines
• Other Chemical additives Functional Additives
• Other Chemical Reagents

Compound Introduction: (R)-(+)-N,N-dimethyl-1-phenylethanamine (CAS No. 19342-01-9)

The compound (R)-(+)-N,N-dimethyl-1-phenylethanamine, identified by the Chemical Abstracts Service Number (CAS No.) 19342-01-9, is a significant molecule in the field of pharmaceutical chemistry and biochemistry. This chiral amine derivative has garnered attention due to its unique structural properties and potential applications in medicinal chemistry. The (R)-configuration of the amine group imparts distinct stereochemical characteristics, which are crucial for its biological activity and interaction with biological targets.

Structurally, (R)-(+)-N,N-dimethyl-1-phenylethanamine consists of a phenyl ring attached to an ethylamine backbone, with N,N-dimethylation enhancing its lipophilicity and metabolic stability. This molecular architecture makes it a valuable scaffold for designing novel pharmacological agents. Recent studies have highlighted its role as a key intermediate in the synthesis of various bioactive compounds, including potential therapeutic agents targeting neurological and cardiovascular disorders.

In the realm of drug discovery, the stereochemistry of (R)-(+)-N,N-dimethyl-1-phenylethanamine is of paramount importance. The (R)-enantiomer exhibits distinct pharmacokinetic and pharmacodynamic profiles compared to its (S)-counterpart, underscoring the significance of chirality in drug design. Advanced computational methods, such as molecular docking and quantum mechanical calculations, have been employed to elucidate the binding interactions of this compound with biological receptors. These studies have revealed that the phenyl group and the dimethyl-substituted amine moiety play critical roles in modulating receptor affinity and specificity.

Current research in medicinal chemistry has explored the derivatization of (R)-(+)-N,N-dimethyl-1-phenylethanamine to develop novel therapeutic entities. For instance, modifications to the phenyl ring or the amine substituents have led to compounds with enhanced efficacy and reduced side effects. One notable area of investigation has been its application in the development of drugs targeting neurotransmitter receptors, such as dopamine and serotonin receptors. These receptors are implicated in various neurological disorders, including depression, anxiety, and Parkinson's disease.

The synthesis of (R)-(+)-N,N-dimethyl-1-phenylethanamine has been optimized using asymmetric synthesis techniques, ensuring high enantioselectivity and yield. Chiral auxiliaries and catalysts, such as BINAP-ruthenium complexes, have been employed to achieve high levels of enantiomeric purity. These advances in synthetic methodology have made it feasible to produce large quantities of this compound for both research and industrial applications.

In addition to its pharmaceutical applications, (R)-(+)-N,N-dimethyl-1-phenylethanamine has shown promise in materials science and chemical biology. Its unique structural features make it a useful building block for designing supramolecular assemblies and functional materials. Furthermore, its interaction with biological macromolecules has been studied to understand fundamental mechanisms in cell signaling and drug action.

The chemical properties of (R)-(+)-N,N-dimethyl-1-phenylethanamine have also been explored for their potential in analytical chemistry. Its chiral nature allows it to be used as a chiral selector in chromatographic techniques, enabling the separation of enantiomeric mixtures with high precision. This application is particularly valuable in quality control processes for pharmaceuticals, where enantiomeric purity is critical.

Recent advancements in biocatalysis have opened new avenues for the production of (R)-(+)-N,N-dimethyl-1-phenylethanamine. Enzymatic methods using engineered microbial strains or isolated enzymes have been developed to achieve sustainable and scalable synthesis. These biocatalytic approaches align with green chemistry principles by reducing waste and energy consumption compared to traditional synthetic routes.

The future prospects for (R)-(+)-N,N-dimethyl-1-phenylethanamine are vast and multifaceted. Ongoing research aims to uncover new therapeutic applications and optimize its synthesis for industrial-scale production. Collaborative efforts between academia and industry are essential to translate laboratory discoveries into clinical reality. As our understanding of molecular interactions continues to evolve, compounds like (R)-(+)-N,N-dimethyl-1-phenylethanamine will undoubtedly play a pivotal role in shaping the future of medicine.

• 140408-77-1(Benzenemethanaminium, α-methyl-N,N,N-tris(phenylmethyl)-, inner salt)
• 5933-40-4((R)-N-Methyl-1-phenylethanamine)
• 19131-99-8((S)-(-)-N-Methyl-1-phenylethylamine)
• 17279-31-1((S)-(-)-N,N-Dimethyl-1-phenethylamine)
• 2449-49-2(N,N,α-trimethylbenzylamine)
• 32512-24-6(methyl(1-phenylethyl)amine)
• 357407-86-4(N,1,2,2,2-Pentadeuterio-1-(2,3,4,5,6-pentadeuteriophenyl)-N-(trideuteriomethyl)ethanamine)
• 7398-61-0( )
• 5336-72-1(N,N-Dimethylbenzhydrylamine)
• 15429-16-0(Benzenemethanamine, N,N-diethyl-a-methyl-)